<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Dejligt link som sukker smed på EI: http:&#x2F;&#x2F;www.gsk.com&#x2F;content&#x2F;dam&#x2F;gsk&#x2F;globals&#x2F;documents&#x2F;pdf&#x2F;media&#x2F;presentations&#x2F;Leerink%20Swann%20invester%20Event%206%20December%202013.pdf GSK skriver direkte planne]]></title><description><![CDATA[<p dir="auto">Dejligt link som sukker smed på EI: <a href="http://www.gsk.com/content/dam/gsk/globals/documents/pdf/media/presentations/Leerink%20Swann%20invester%20Event%206%20December%202013.pdf" rel="nofollow ugc">http://www.gsk.com/content/dam/gsk/globals/documents/pdf/media/presentations/Leerink Swann invester Event 6 December 2013.pdf</a> GSK skriver direkte planned and ongoing combination studies with Ibrutinib and Idelalisib</p>
]]></description><link>https://dev.proinvestor.com/forum/topic/450128/dejligt-link-som-sukker-smed-p-ei-httpwwwgskcomcontentdamgskglobalsdocumentspdfmediapresentationsleerink20swann20invester20event20620december202013pdf-gsk-skriver-direkte-planne</link><generator>RSS for Node</generator><lastBuildDate>Sun, 14 Jun 2026 01:18:07 GMT</lastBuildDate><atom:link href="https://dev.proinvestor.com/forum/topic/450128.rss" rel="self" type="application/rss+xml"/><pubDate>Mon, 19 Feb 2018 18:16:51 GMT</pubDate><ttl>60</ttl></channel></rss>